[Experience with UroBest in patients with acute cystitis].

Q4 Medicine
Urologiia Pub Date : 2024-09-01
S Kyzlasov P, A Neymark B, V Kuzmenko A, G Abuev G, A Gyaurgiev T, A Kuzmenko G
{"title":"[Experience with UroBest in patients with acute cystitis].","authors":"S Kyzlasov P, A Neymark B, V Kuzmenko A, G Abuev G, A Gyaurgiev T, A Kuzmenko G","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the efficacy and safety of UroBest complex in sachets for combined therapy of patients with acute cystitis in comparison with products of similar composition.</p><p><strong>Materials and methods: </strong>The randomized multi-center study included 90 patients with acute cystitis aged 18 to 49 years who were treated at the clinical bases of SRC FMBC, FMBA of Russia, Moscow, Russia, Altai State Medical University and Voronezh State Medical University named after N.N. Burdenko. Patients of all groups received Fosfomycin trometamol in a dosage of 3g once, at night. Depending on the additional drug received, they were divided into 3 groups of 30 patients each. In group 1, they took UroBest 1 sachet daily for 7 days from the first day of therapy, NefroBest-N one capsule 2 times a day for 1 month also from the first day of therapy, in combination with UroBest complex in the first week. In group 2, UroBest 1 sachet daily for 7 days was administered, while in group 3, biologically active supplement (BAA) \"Uronext\" 1 sachet daily for 7 days was given. The study included 4 control points, where the degree and dynamics of changes in laboratory parameters (urinalysis, complete cell count, urine culture with determination of sensitivity to antibiotics), quality of life according to the questionnaire, and pain intensity according to the visual analogue scale (VAS) were assessed, as well as the drug tolerability based on the analysis of adverse events.</p><p><strong>Results: </strong>The efficacy and safety data were evaluated. Administration of complex preparations with extracts of medicinal plants as an additional to antibacterial therapy led to significant improvement of all parameters, except for the level of leucocytes in the complete cell count. The most pronounced improvement was observed in groups 1, and lesser improvement was noted in group 2. One patient in group 3 had an adverse event, which was resolved spontaneously.</p><p><strong>Conclusion: </strong>UroBest has a favorable efficacy and safety profile. According to our experience, combination of UroBest and NefroBest-N complexes leads to more pronounced positive changes in laboratory parameters and patient's condition according to the questionnaires compared to UroBest as monotherapy and, to an even greater extent, to the biologically active supplement UroNext.</p>","PeriodicalId":23546,"journal":{"name":"Urologiia","volume":" 4","pages":"41-47"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologiia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: To evaluate the efficacy and safety of UroBest complex in sachets for combined therapy of patients with acute cystitis in comparison with products of similar composition.

Materials and methods: The randomized multi-center study included 90 patients with acute cystitis aged 18 to 49 years who were treated at the clinical bases of SRC FMBC, FMBA of Russia, Moscow, Russia, Altai State Medical University and Voronezh State Medical University named after N.N. Burdenko. Patients of all groups received Fosfomycin trometamol in a dosage of 3g once, at night. Depending on the additional drug received, they were divided into 3 groups of 30 patients each. In group 1, they took UroBest 1 sachet daily for 7 days from the first day of therapy, NefroBest-N one capsule 2 times a day for 1 month also from the first day of therapy, in combination with UroBest complex in the first week. In group 2, UroBest 1 sachet daily for 7 days was administered, while in group 3, biologically active supplement (BAA) "Uronext" 1 sachet daily for 7 days was given. The study included 4 control points, where the degree and dynamics of changes in laboratory parameters (urinalysis, complete cell count, urine culture with determination of sensitivity to antibiotics), quality of life according to the questionnaire, and pain intensity according to the visual analogue scale (VAS) were assessed, as well as the drug tolerability based on the analysis of adverse events.

Results: The efficacy and safety data were evaluated. Administration of complex preparations with extracts of medicinal plants as an additional to antibacterial therapy led to significant improvement of all parameters, except for the level of leucocytes in the complete cell count. The most pronounced improvement was observed in groups 1, and lesser improvement was noted in group 2. One patient in group 3 had an adverse event, which was resolved spontaneously.

Conclusion: UroBest has a favorable efficacy and safety profile. According to our experience, combination of UroBest and NefroBest-N complexes leads to more pronounced positive changes in laboratory parameters and patient's condition according to the questionnaires compared to UroBest as monotherapy and, to an even greater extent, to the biologically active supplement UroNext.

[急性膀胱炎患者使用 UroBest 的经验]。
目的:与类似成分的产品相比,评估袋装复方 UroBest 用于急性膀胱炎患者综合治疗的有效性和安全性:这项随机多中心研究纳入了 90 名急性膀胱炎患者,他们的年龄在 18 至 49 岁之间,分别在俄罗斯莫斯科、阿尔泰国立医科大学和以 N.N. Burdenko 命名的沃罗涅日国立医科大学的 SRC FMBC、FMBA 临床基地接受治疗。各组患者均在夜间接受一次剂量为 3 克的磷霉素妥美他莫。根据额外服用药物的不同,他们被分为 3 组,每组 30 人。在第 1 组中,他们从治疗的第一天起每天服用 1 袋优降宝,连续服用 7 天;从治疗的第一天起每天服用 2 次奈福霉素胶囊,连续服用 1 个月,并在第一周与优降宝复方制剂一起服用。第 2 组每天服用 1 袋 UroBest,连续服用 7 天;第 3 组每天服用 1 袋生物活性补充剂(BAA)"Uronext",连续服用 7 天。研究包括 4 个对照点,在这些对照点上评估了实验室参数(尿液分析、全细胞计数、尿培养及抗生素敏感性测定)的变化程度和动态,根据问卷调查评估了生活质量,根据视觉模拟量表(VAS)评估了疼痛强度,并根据不良事件分析评估了药物耐受性:结果:对疗效和安全性数据进行了评估。作为抗菌治疗的补充,服用含有药用植物提取物的复方制剂可显著改善除全细胞计数中的白细胞水平外的所有参数。第 1 组的改善最为明显,第 2 组的改善较小。第 3 组的一名患者出现了不良反应,但已自行缓解:结论:UroBest 具有良好的疗效和安全性。根据我们的经验,UroBest 和 NefroBest-N 复合物的组合与 UroBest 作为单一疗法相比,在实验室参数和问卷调查显示的患者状况方面带来了更明显的积极变化,而与生物活性补充剂 UroNext 相比,效果更为显著。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Urologiia
Urologiia Medicine-Medicine (all)
CiteScore
0.80
自引率
0.00%
发文量
160
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信